Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471 is registered in ClinicalTrials.gov with Genelux Corporation as lead sponsor.

NCT NCT05281471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05281471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Lead sponsor
Genelux Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2022
Completion date
December 31, 2027
Enrollment
186 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

endometrioid ovarian cancer, fallopian tube cancer, high-grade serous ovarian cancer, ovarian clear cell carcinoma, platinum-refractory ovarian cancer, platinum-resistant ovarian cancer, primary peritoneal cancer